Friends, two things in Britain are back to more or less where they were at the beginning of last week: Gary Lineker and the Silicon Valley Bank UK. And yet, after breaking a vase, the pieces never come back together in perfection. Decency and bank deposits are guaranteed (so far). Richard Sharp might be out of the job soon and SVB shareholders’s money is gone too. Rather minimal week in funding news and yet very evenly distributed: Cambridge, Swansea, Belfast, Nottingham and London. Opto Biosystems has launched with £1.85 million pre-seed funding to translating minimally invasive implantable neurotechnology to fight hard-to-treat diseases. CanSense has raised £1.5 million to develop its colonoscopy technology, aiming to detect pre-malignant polyps before these develop into cancer. It turns out the former Google CEO Eric Schmidt is in talks to donate £16 million to the UK Biobank. This news came out as part of the plan the UK government is setting out to turning the country into a science superpower. There are a few important bits of policy this week but perhaps reforming the UK regulation for university spinouts ranks first. To do so, the government has appointed Prof Irene Tracey CBE and Dr Andrew Williamson, so we are in good hands. Two major Board announcements: MitoRx Therapeutics and EyeBio. Worth looking into their science too. Now, if you were worrying we would all need to lose a few pounds to be able to fit into the available lab space in the Triangle, we are not there yet. Abstract Securities has been granted detailed planning consent for the South Cambridge Science Centre and Bruntwood SciTech will invest £60 million into Manchester Science Park to create 131,000 sq ft of lab space. PetMedix has announced a new proprietary pain treatment for dogs and Stevenage-based Autifony Therapeutics has reported to have discovered certain compounds acting as voltage-gated potassium channels modulators from the Kv3 subfamily. Talking about pain, the Interesting readings section features a piece about the relationship between the University of Oxford and the Sackler family. and another one on the reasons behind London’s listing miasma. On that regard, Adaptimmune has acquired TRC therapeutics (good one, Bent!) and/but the combined company will trade on NASDAQ. Music by the Pet Shop Boys and Paul Cézanne, Vincent van Gogh and Paul Gauguin to remind us the beauty of life. Let’s dive in!

Cambridge-based Opto Biosystems has launched with £1.85 million pre-seed funding. The investment was led by Blackbird Ventures, with support from Possible Ventures and Amar Shah among others. The funding will help accelerate Opto's mission of translating minimally invasive implantable neurotechnology to fight hard-to-treat diseases. Opto collaborates with a consortium of leading clinicians to redefine the standard of care with data and technology. The investment will be used to expand its engineering team and push towards validation of its core technology platform. Opto is led and co-founded by Ben Woodington, PhD (ex-medical device engineer and bioelectronics researcher) and Elise Jenkins, PhD (electrical engineer turned neuro-oncology researcher).

Swansea-based CanSense has raised £1.5 million investment. The funding was participated by Mercia, the Development Bank of Wales, and Nonacus. CanSense has developed a blood test that can detect early-stage bowel cancer. The test combines laser spectroscopy with AI, is less invasive and expensive than a colonoscopy, and could help detect pre-malignant polyps before they develop into cancer. The proceedings of the round will be used to further develop the product and carry out clinical trials. Early detection of bowel cancer significantly improves outcomes for patients. Bowel cancer is the second most common cause of cancer deaths in the UK, accounting for over 16,800 deaths each year. The company was found in 2019 based on research from Prof Peter Dunstan, Prof Dean Harris and Dr Cerys Jenkins at Swansea University which was part funded by Cancer Research Wales.

Belfast-based GenoME Diagnostics has raised £1.4 million in pre-Series A. The round was supported by QUBIS, Co-Fund NI (managed by Clarendon Fund Managers), and Deepbridge Capital, and includes an additional £500,000 InnovateUK Biomedical Catalyst grant for a project in collaboration with QUB. The proceedings of the round will be used to develop its OvaME product which improves ovarian cancer testing results through measuring levels of patented DNA methylation markers in blood samples. GenoME also plans to file for EU regulatory approval and expand its regulatory approach to the UK and North America. The company's diagnostic pipeline can also be utilised for biomarker discovery in other disease areas. The company is led by **Dr Shannon Beattie (CEO), and Prof Paul Mullan (co-founder and CSO).

Nottingham-based NuVision Biotherapies has raised £1.1 million pre-Series A. The investment was participated by existing investors, including MEIF Proof of Concept & Early Stage Fund, Mercia’s EIS funds, Pioneer Group, the University of Nottingham, and private investors. This investment will enable NuVision to speed up the development of its first two products before a Series A investment in the next year. NuVision's wound dressings, made from amniotic membrane, help regenerate and heal the eye's surface, and its first product, Omnigen, is already approved for treatment on the NHS. Omnigen can be used in hospitals and private clinics in the UK and abroad, either in the operating theatre or with the company's proprietary bandage contact lens, OmniLenz. The latest funding brings the total raised by NuVision to over £5 million. NuVision was founded in 2015 by Dr Andy Hopkinson based on his research at the University of Nottingham.

London-based Mendelian has secured a £1.4 million grant from the Artificial Intelligence in Health and Care Awardsfor its AI case-finding tool that diagnoses rare diseases at scale. Mendelian is one of nine recipients of the AI Awards' latest round of funding, which invested £16 million into pioneering artificial intelligence research. NHS AI Lab, an R&D initiative of the UK national health service, runs the AI Awards in partnership with the National Institute for Health and Care Research and Accelerated Access Collaborative. With its MendelScan algorithm, Mendelian compares symptoms of over 100 rare pathologies with disease data from large batches of electronic patient health records. It estimates that 3.5 million people in the UK are living with an undiagnosed rare condition.

London-based This has raised £15 million in series B funding to fuel ongoing growth. The funding round included £4.7 million from the Seedrs platform last year and more than £10 million from investors including BGF, Lever VC, Backed, Five Seasons Ventures, ECG Research, CJ Corporation and Kreos Capital. This is a meat-alternative producer. The investment will be used to consolidate the company’s supply chain, fund outdoor advertising campaigns, build R&D capabilities, and take the brand overseas in 2023. This also recently launched its best-selling plant-based bacon, and has launched 15 new products in three categories in 2022, taking the brand into frozen, ready meals, and food-to-go, as well as launching its first beef alternatives.

Former Google CEO Eric Schmidt is in talks to donate £16 million to UK Biobank, which collects DNA from 500,000 British volunteers and uses the data to study genetics and diseases. The project has already received funding from Mark Zuckerberg and Priscilla Chan. The funding talks were announced as part of a £360 million package to boost the UK's science and technology industries. The UK government will invest up to £50 million in research projects, such as the gene database, alongside co-investment from philanthropists like Schmidt. The government has also earmarked £250 million for funding AI, quantum computing, and bioengineering projects, and £50 million for new lab space for researchers.

The British Business Bank is launching a £70 million investment fund this autumn to drive growth for smaller businesses in Northern Ireland as well as a £130 million Wales fund. It aims to increase the supply and diversity of early-stage finance for smaller businesses in Northern Ireland and is part of a series of similar funds being launched by the British Business Bank. The Investment Fund for Northern Ireland as well as the Wales fund will offer loans ranging from £25,000 to £2 million and equity investment up to £5 million. It will operate across two tiers: debt (£25k-£2m) and equity (up to £5m). The British Business Bank's core programmes support over £12.2 billion¹ of finance to more than 96,000 smaller businesses. The bank is inviting proposals from potential fund managers to operate the new Investment Fund for Wales and Northern Ireland.

UK tech startups will be affected by changes to the Research and Development (R&D) Tax Credits System. The changes, which were first announced by Chancellor Jeremy Hunt last year, are intended to reduce the number of fraudulent R&D tax relief claims and streamline the system. The changes have been heavily criticised by the UK tech industry, with smaller companies saying they will be less incentivised to invest in technological innovation. The R&D tax credit system was introduced in the UK in 2000 and offers financial incentives to companies developing new technologies. There are currently two R&D tax relief regimes, one for small and medium-sized companies and one for larger companies. The SME R&D deduction rate will drop from 130% to 86%, while the surrendaible losses rate will drop from 14.5% to 10%. The RDEC rate will increase from 13% to 20%. Furthermore, HMRC will be introducing a more rigorous verification process for applying firms.

The UK government has launched a plan to make the country a science and technology superpower by 2030. The plan aims to boost the economy, create high-paid jobs, protect security, and improve people’s lives through innovation and technology. The plan includes 10 key actions, such as identifying and pursuing critical technologies, increasing investment in research and development, and attracting global talent. The new Science and Technology Framework will bring together every part of the government, with an initial investment of over £370 million.

The UK government has appointed Prof Irene Tracey CBE (Vice-Chancellor of the University of Oxford and member of the Medical Research Council of UK Research and Innovation) and Dr Andrew Williamson (Chair of the Venture Capital Committee at the British Private Equity & Venture Capital Association and Managing Partner of Cambridge Innovation Capital) to review the UK spin-out landscape. The UK university sector plays an integral role in supporting economic growth and fuelling innovation. Investment in UK university spin-outs has increased more than five-fold to £5 billion in 2021. The review aims to identify best practices double down in promoting innovation and business growth. This is part of the Chancellor's vision to nurture the world's next Silicon Valley.

London-based EyeBio has announced details on Restoret. Restoret is its first asset in a diversified pipeline of multi-specific agonist antibodies targeting the Wnt pathway, with plans for IND filing in Q2 2023. EyeBio aims to develop a new generation of therapies for eye diseases. This constitutes the first time Wnt pathway is going to be used in clinical translation in the eye-diesease context. Research has shown that Wnt signaling in the retina plays a central role in the maintenance of vascular integrity, and defects in Wnt signaling cause retinal vascular leakage. Restoret has demonstrated efficacy in preclinical ophthalmic models and in genetic models. The company has also in-licensed a second bispecific agonist antibody asset for the treatment of retinal diseases, with a separate and complementary mechanism of action to Restoret.

Edinburgh-based Calcivis has received pre-market approval from the US Food and Drug Administration. This makes Calcivis the first Scottish medical device to receive such an accreditation. The Calcivis Imaging System aims to improve the standard of care in the dental sector by allowing dentists to visualise decay on patients' teeth in real-time. The imaging system applies a patented photoprotein which, in the presence of free calcium ions released from an actively decaying tooth surface, produces a very short, low-level light flash. An integrated intra-oral sensor within the imaging device detects the luminescence and presents clinicians with a chair-side demineralisation map. With the approval, Calcivis plans to establish a US commercial capability in Boston and is building a team in America to take its technology to market. The company has raised £16 million from investors including Archangels and Scottish Enterprise since it was founded in 2012.

A stem cell-derived nerve cell transplant has been given to a Parkinson's patient for the first time ever. The product, developed by Lund University, replaces lost dopamine nerve cells in the parkinsonian brain. The patient was the first of eight with Parkinson’s disease who will receive the transplant from Sweden and the UK. The selected candidates were diagnosed with Parkinson's at least ten years ago and are at a moderate stage of their disease. The STEM-PD trial aims to replace the lost dopamine cells with healthy ones manufactured from stem cells. The product has undergone pre-clinical tests and is expected to mature into new and healthy dopamine producing nerve cells within the brain. The trial is managed by Cambridge Clinical trials unit Neuroscience theme and Skane University Hospital Neurology Research Unit. The development of the product and the trial is funded by national and EU funding agencies and Novo Nordisk A/S.

Bristol-based eXmoor and Imophoron have signed a partnership to develop vaccines for clinical use. The agreement will initially focus on developing manufacturing platforms for Imophoron's lead candidate vaccine for Respiratory Syncytial Virus (RSV). The project will then move to transferring the process to GMP manufacturing at eXmoor's new Cell and Gene Therapy Centre in Bristol, UK. Imophoron will benefit from eXmoor's 19 years of experience in process development and manufacturing strategies, allowing Imophoron to focus on its novel vaccine development. Imophoron's ADDomer platform aims to generate vaccine candidates for a range of diseases that can be administered through various routes without requiring sub-temperature storage. Their lead target is RSV, a disease affecting children and the elderly with no currently approved vaccine.

Singapore-based Hummingbird Bioscience has exercised its option to license clinical trial results from Cancer Research UK of HMBD-001. HMBD-001 is a differentiated and potentially best-in-class HER3-targeting antibody and the collaboration between Hummingbird and CRUK has been pivotal for its development of HMBD-001 as precision therapy. The Phase 1/2aclinical trial in the UK is being sponsored and managed by CRUK’s Centre for Drug Development, and aims to identify a recommended Phase 2 dose for further evaluation. CRUK will continue the ongoing Phase 1/2a study by completing the ongoing dose escalation portion, followed by a dose expansion study in metastatic castrate-resistant prostate cancer later this year.

Cambridge-based PetMedix has announced a new pain treatment for dogs, called PET005. A US patent has been granted for this molecule. PET005 is a fully canine biotherapeutic that leverages natural receptors to reduce Nerve Growth Factor levels and alleviate pain. It has been effective in treating various pain types, including osteoarthritis, neuropathic, and cancer-related pain. The candidate has shown promising results in rodent chronic pain and canine acute pain models, with superior biophysical properties and stability. PetMedix is a biotherapeutics company targeting a broad range of indications across two species and the patent grant and trial data reinforce that they are on the right track.

Cancer Research UK and Belgium-based UCB have signed a collaboration agreement to develop two investigational antibody candidates, UCB6114 and UCB4594, for cancer treatment. The collaboration brings together the translational research and clinical development capabilities of Cancer Research UK with UCB's antibody discovery expertise. Cancer Research UK's Centre for Drug Development will lead the design, preparation, sponsorship, and delivery of Phase 1/2 clinical trials for both candidates, and will appoint the chief clinical and scientific investigators. UCB will manufacture both investigational antibody candidates and retain exclusive rights to further develop and commercialise both assets. Financial details of the partnership were not disclosed.

Stevenage-Autifony Therapeutics reports to have discovered compounds acting as voltage-gated potassium channels modulators from the Kv3 subfamily (Kv3.1, Kv3.2 and/or Kv3.3) with potential therapeutics use in myoclonic epilepsy, among others.

Oxford-based MitoRx Therapeutics has appointed Christine Charman, PhD as Chief Development Officer, David Richardson as Finance Director, and four new members to its Scientific Advisory Board. Dr Chapman was Senior Global Program Lead for Takeda’s Rare Diseases, Respiratory and Immunology and Neuroscience therapy areas. She also served as Program Lead supporting UK Vaccine and Antiviral Task Forces. David Richardson, BSc ACMA AMCT has over 30 years of experience including senior finance roles in AstraZeneca and Evotec. The board includes Prof Chas Bountra OBE (Pro-Vice Chancellor for Innovation at the University of Oxford), Prof Dame Kay Davies, CBE DBE FRS FMedSci (Dr Lee’s Professor of Anatomy Emeritus at the University of Oxford and co-director of the MDUK Oxford Neuromuscular Centre), Prof Laurent Servais (Director of the Specialised Translational Research Oxford Neuromuscular Group), and Dr Bernd C Schwahn, MD PhD FRCPCH (Honorary Clinical Senior Lecturer in Genomic Medicine). MitoRx aims to become a global leader in treating diseases caused by impaired mitochondrial function. The company is developing small molecules that are being pre-clinically tested in a mammalian model of muscular dystrophy. The company's compounds have been shown to suppress fibrosis in a murine chronic obstructive pulmonary disease model, reduce loss of function, and immune cell infiltration. Additionally, MitoRx has demonstrated the first complete restoration of movement in a dys-1 model of Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. MitoRx indicates there are only a few weeks left for subscribers to make commitments to invest in MitoRx’s Advanced Subscription Agreement (ASA).

Oxford-based Harwell Campus has been selected by Moderna has chosen to host its Moderna Innovation and Technology Center (MITC). The MITC will include a research, development, and manufacturing facility, as well as a clinical biomarker laboratory. The facility will provide the UK public with access to cutting-edge mRNA vaccines for respiratory diseases, subject to regulatory approval. Construction will commence during 2023, and the facility is anticipated to become operational in 2025. It will create hundreds of jobs across Oxfordshire and the UK, and cement Harwell Campus as a national health tech hub for the pioneering research and development of mRNA and other nucleic acid therapeutics.

Bruntwood SciTech will invest £60 million into Manchester Science Park to create 131,000 sq ft of lab space. The new space will support life science businesses working in diagnostics, genomics, and precision medicine. The development will offer a range of CL2 labs with supporting office space from 2,500 sq ft to 22,000 sq ft floors. The BREEAM Excellent development will be environmentally friendly, aiming to achieve net zero carbon in construction and operation. The redevelopment of Greenheys will expand the existing life science cluster at Manchester Science Park, which is home to more than 150 businesses spanning biotech, precision medicine, diagnostics, digital health, cyber security, digital technology, medtech and light manufacturing. The new development is subject to planning approval by Manchester City Council.

The Francis Crick Institute is building an 11,800-square-foot life sciences laboratory on its roof. The lab, called Skylab, will be used for scientific partnerships, and MSD (NYSE: MRK) will be the first to lease it for three years. The aim is to maximise the exploitation of knowledge for societal benefit and the wider UK economy by providing additional laboratory space to expand partnership opportunities and increase the permeability of Crick science to the outside world. The partnership between Crick and MSD will address scientific problems or challenges brought forward by Crick researchers to understand age-related diseases, including the onset of neurodegeneration, by building models of Parkinson's disease using state-of-the-art stem cell technologies.

Abstract Securities has been granted detailed planning consent for the South Cambridge Science Centre (SCSC). The SCSC which will be a flexible laboratory for life sciences and biotechnology occupiers, offering much-needed new laboratory space in Cambridge. The SCSC will be built on a brownfield site in Sawston, around six miles from Cambridge City Centre and close to Babraham Research Park, Granta Park, and Unity Campus. The project will be delivered in two phases, with the first building of 140,000 sq. ft. ready for occupation in early 2025. Abstract is already in early discussions with a number of parties interested in the scheme.

London-based EyeBio has announced the appointment of senior executives. Anthony P. Adamis, M.D., has been appointed Chief Scientific Officer. Dr. Adamis co-founded EyeBio in 2021 and Eyetech in 2002. Prior to that, he served as Senior Vice President of Product Development and Development Innovation at Genentech. Loni Da Silva has been appointed Chief Regulatory Officer, bringing extensive ophthalmology regulatory leadership experience and led to Macugen’s approval, the first retinal drug; Frances Betts has been appointed Global Head, Clinical Operations, having recruited thousands of patients into more than 20 ophthalmology clinical trials; Mike Davies will serve as Chemistry, Manufacturing, and Control (CMC) Lead. He led protein sciences for the development of bispecific antibodies at F-Star Therapeutics; and Eric Ng, Ph.D., Senior Vice President, Biology, and Associate Professor in Ophthalmology at Harvard University.

London-based Vitrarka Therapeutics has appointed Dr Peter Simpson as Chief Scientific Officer and Board member. Dr Simpson is Honorary Professor at the University of Manchester and Chief Scientific Officer at Medicines Discovery Catapult. Vitrarka is developing RNAi therapies and non-viral delivery platform technology to promote the immune response normalise the tumour vasculature. Dr Simpson will collaborate in progressing the company’s EndoPore to the clinic.

Aberdeen-based Elasmogen has appointed Dr Jane Dancer as Chair of the Board. Dr Dances was Chief Business Officer at F-star, Vice President of Business Development at Cellzome, and Director of Business Development at Cambridge Antibody Technology. Currently, she is on the board of Spirea, PharmEnable, Macomics and NanoSyrinx. Elasmogen is developing a pipeline of novel targeting single domain biologics known as soloMERsTM for inflammatory disease and cancer.

Edinburgh-based Resolution Therapeutics has appointed Eli Gilsohn, PhD, MBA as Vice President, Intellectual Property. Prior to joining Resolution, he served Vice President, Intellectual Property at Tropic Biosciences, where he looked after the IP agreements required to form Tropic’s spin-out company, Laverock Therapeutics. The company is developing macrophage cell therapy to treat inflammatory organ disease. The company was founded based on a collaboration between Edinburgh’s Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited.

Cambridge-based Cambridge Innovation Capital (CIC) has appointed Dipesh Patel, PhD as Operating Partner. Dr Patel will focus on technology investments. Prior to CIC, he was Chief Technology Officer at Arm, where he was a member of the Executive Committee at Arm since 2013. Prior to this, Dipesh served as President of the IoT Services Group.

London-based Claret Capital Partners has promoted Paul Bramley to Chief Financial Officer and Operational Partner.

Oxford-headquartered Adaptimmune Therapeutics (NASDAQ: ADAP) and Massachusetts-headquartered TCR² Therapeutics (NASDAQ: TCRR) have announced a merger to create a T cell therapy company for solid tumors. The companies have complementary technology platforms, with a cash runway extended into 2026 after the all-stock transaction. The two companies lead candidates Adaptimmune’s MAGE-A4-targeting afami-cel and TCR²’s mesothelin-targeting gavo-cel will be part of the resulting pipeline as well as candidates engineered with T cell receptors, or TCRs which can target intracellular oncology antigens. Following the merger, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company. The merger is expected to close in Q2 2023, subject to approvals and satisfaction of other closing conditions. The combined company will trade on Nasdaq under the symbol "ADAP" and will be led by Adrian Rawcliffe, CEO of Adaptimmune. The Board of Directors will be composed of three members from TCR2 and six continuing from Adaptimmune.

London-headquartered Orchard Therapeutics (NASDAQ: ORTX) is seeking to raise $188 million in funding to extend its runway to regulatory approval. The financing include a securities purchase agreement and private placement of warrants, with current backing from RA Capital, Deep Track Capital, Cowen Healthcare, Woodline Partners and Zentree Investments. Orchard is focused on obtaining US clearance for OTL-200, a gene therapy for metachromatic leukodystrophy. The therapy has already been approved in the EU under the name Libmeldy, and brought in $18.8 million in 2021. Following a pre-BLA meeting with the FDA, expected next quarter, the company anticipates announcing an intent to request FDA approval.

Exscientia (NASDAQ: EXAI) has announced a collaboration with Charité to develop a precision medicine platform for patients with haematological cancers. The collaboration will involve Charité evaluating Exscientia's precision medicine platform to select better treatments and improve outcomes for patients. The results of the EXALT-1 study, which demonstrated improved outcomes for late-stage haematological cancer patients using Exscientia's deep learning-based high content functional drug testing platform to guide personalised treatment recommendations, will be expanded upon. Charité will also establish a biobank of live human tissue samples to support further technology development and preclinical research projects at both Exscientia and Charité.

AEGEAN Phase III trial results showed that using AstraZeneca's Imfinzi in combination with chemotherapy before and after surgery can significantly improve event-free survival for patients with resectable non-small cell lung cancer. The trial demonstrated a statistically significant increase in event-free survival versus neoadjuvant chemotherapy alone followed by surgery. Lung cancer is a leading cause of cancer death, with non-small cell lung cancer accounting for about 80-85% of all patients diagnosed with lung cancer. Early-stage lung cancer diagnoses are often made when the cancer is found on imaging for an unrelated condition. The AEGEAN results provide evidence that this novel durvalumab regimen can drive improved outcomes in this curative-intent setting.

London-headquartered Small Pharma (TSXV: DMT) (OTCQB: DMTTF) has announced further positive results from its Phase IIa trial of SPL026 for the treatment of Major Depressive Disorder (MDD). The trial showed that patients experienced clinically relevant improvements in mood and function following at least a single dose of SPL026 with supportive therapy. Improvements in anxiety symptoms and wellbeing were also observed following treatment. The results support the rapid and sustained therapeutic profile of SPL026 for the treatment of MDD. Full trial results will be submitted for publication in a peer-reviewed journal.

Cambridge-headquartered F-star Therapeutics has received clearance from the Committee on Foreign Investment in the United States (CFIUS) for its acquisition by invoX Pharma Limited. The acquisition is an all-cash deal, and CFIUS clearance was the final regulatory approval required for the merger to be completed.

Labiotech has talked to Charli Batley (COO, Phoremost), Fiona McLaughlin (CSO, Avacta Therapeutics), Debora Lucarelli (CEO, Enhanc3D Genomics), Maureen Coleman (Chair, CN Bio), Tamsin Mansley (President, Optibrium Inc.) and Sheelagh Frame (CSO, Ubiquigent) about their observations on women in the life sciences industry.

Craig Coben (former Global Head of Equity Capital Markets at Bank of America and Managing Director at Seda Experts) has published a piece in the Financial Times about the challenges for the UK tech companies to listing in London. He discuses how to turn Arm move to the US as a wake up call and the risks of half-way policies that lead to crowding out effect.

Imperial College London has written an article about its span out company Eden Bio and its yeast optimisation technology for precision fermentation.

BBC piece on the UN High Seas Treaty after the United Nations members finally agreed to the first ever treaty to protect the world's oceans outside beyond its frontiers.

Europe will lose out on medical innovation if draft EU reforms pass, says Novo Nordisk CEO.

Rather shocking piece on the relationship between the University of Oxford with the Sackler family… even after the deadly US opioid epidemic was unveiled.